Introduction

Dasatab 20 mg (Dasatinib) Tablet is a highly effective tyrosine kinase inhibitor designed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL). Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Onco Solution, Dasatab 20 mg (Dasatinib) Tablet targets BCR-ABL and SRC family kinases, offering a potent therapeutic option for patients resistant or intolerant to prior therapies. With its proven efficacy and manageable safety profile, Dasatab 20 mg (Dasatinib) Tablet is a cornerstone in modern oncology protocols.

Indications

Dasatab 20 mg (Dasatinib) Tablet is indicated for:

1. Newly Diagnosed Ph+ CML: Chronic phase in adults and pediatric patients ≥1 year.
2. Resistant/Intolerant Ph+ CML: Chronic, accelerated, or blast phase in adults.
3. Ph+ ALL: Adults with resistance or intolerance to prior therapy.
4. Pediatric Ph+ CML: Chronic phase in children ≥1 year.

Pharmacology

Dasatab 20 mg (Dasatinib) Tablet exerts its therapeutic effects by:

• Inhibiting BCR-ABL, SRC family kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ.
• Overcoming resistance to imatinib through binding to multiple conformations of the ABL kinase.
• Inducing apoptosis in Ph+ CML and ALL cell lines.

Pharmacokinetics:

• Absorption: Peak plasma concentrations achieved within 0.5–6 hours.
• Distribution: 96% plasma protein binding; apparent volume of distribution: 2505 L.
• Metabolism: Primarily by CYP3A4; active metabolite contributes 5% of total AUC.
• Excretion: 85% fecal and 4% renal excretion within 10 days.

Dosage & Administration

Dasatab 20 mg (Dasatinib) Tablet is administered orally under the supervision of an oncology specialist.

Recommended Dosage:

• Adults:
  • Chronic Phase CML: 100 mg once daily.
  • Advanced Phase CML/Ph+ ALL: 140 mg once daily.
• Pediatrics:
  • 10–20 kg: 40 mg once daily.
  • 20–30 kg: 60 mg once daily.
  • 30–45 kg: 70 mg once daily.
  • ≥45 kg: 100 mg once daily.

Administration Guidelines:

• Swallow tablets whole; do not crush, cut, or chew.
• Can be taken with or without food.

Drug Interactions

• Strong CYP3A4 Inhibitors: Increase dasatinib exposure; avoid or reduce dose.
• Strong CYP3A4 Inducers: Decrease dasatinib exposure; avoid or increase dose.
• Gastric Acid Reducers: Decrease dasatinib absorption; use antacids 2 hours before or after dosing.

Contraindications

• Hypersensitivity to dasatinib or any component of the formulation.

Side Effects

Common Adverse Reactions:

• Hematologic: Myelosuppression (thrombocytopenia, neutropenia, anemia).
• Gastrointestinal: Nausea, vomiting, diarrhea.
• Cardiovascular: Fluid retention, pleural effusion, QT prolongation.

Serious Risks:

• Pulmonary arterial hypertension (PAH).
• Severe bleeding events.
• Tumor lysis syndrome.

Pregnancy & Lactation

• Pregnancy Category D: Dasatab 20 mg (Dasatinib) Tablet may cause fetal harm. Avoid pregnancy during treatment and for 30 days post-treatment.
• Lactation: Discontinue breastfeeding during treatment and for 2 weeks after the final dose.

Precautions & Warnings

• Myelosuppression: Monitor CBCs regularly; manage with dose adjustments.
• Bleeding: Avoid concomitant anticoagulants or antiplatelet agents.
• Fluid Retention: Monitor for pleural effusion; manage with diuretics or dose reduction.
• PAH: Evaluate cardiopulmonary status before and during treatment.

Overdose Management

No specific antidote exists. Provide supportive care, including:

• Monitoring for myelosuppression.
• Managing bleeding events.
• Correcting electrolyte imbalances.

Storage Conditions

• Store below 30°C in a dry place.
• Protect from light and keep out of reach of children.

Manufacturing Excellence

Dasatab 20 mg (Dasatinib) Tablet is manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified company with over 30 years of expertise in oncology therapeutics. Their state-of-the-art facilities ensure:

• Rigorous quality control.
• Compliance with international standards.

Global Supply Network

Onco Solution, the global supplier of Dasatab 20 mg (Dasatinib) Tablet, guarantees:

• Reliable, temperature-controlled logistics.
• Compliance with global regulatory requirements.

Clinical Value Proposition

Dasatab 20 mg (Dasatinib) Tablet offers:

• Targeted inhibition of BCR-ABL and SRC kinases.
• Proven efficacy in Ph+ CML and ALL.
• Flexible dosing for adults and pediatric patients.

Conclusion

Dasatab 20 mg (Dasatinib) Tablet is a vital therapeutic option for Ph+ CML and ALL, combining clinical efficacy with a manageable safety profile. Backed by Eskayef Pharmaceuticals Ltd.’s manufacturing excellence and Onco Solution’s global distribution network, Dasatab 20 mg (Dasatinib) Tablet ensures reliable access to life-saving oncology care.